MetLife Investment Advisors LLC lowered its holdings in shares of Cabot Corp (NYSE:CBT) by 2.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 36,601 shares of the specialty chemicals company’s stock after selling 1,086 shares during the period. MetLife Investment Advisors LLC owned 0.06% of Cabot worth $1,572,000 as of its most recent filing with the SEC.
A number of other institutional investors have also bought and sold shares of the stock. Lindbrook Capital LLC acquired a new stake in shares of Cabot in the fourth quarter valued at approximately $28,000. Meeder Asset Management Inc. raised its position in shares of Cabot by 28.2% in the fourth quarter. Meeder Asset Management Inc. now owns 1,049 shares of the specialty chemicals company’s stock valued at $45,000 after buying an additional 231 shares in the last quarter. IFP Advisors Inc raised its position in shares of Cabot by 723.5% in the fourth quarter. IFP Advisors Inc now owns 1,087 shares of the specialty chemicals company’s stock valued at $46,000 after buying an additional 955 shares in the last quarter. Bremer Trust National Association acquired a new stake in shares of Cabot in the fourth quarter valued at approximately $50,000. Finally, Ipswich Investment Management Co. Inc. acquired a new stake in shares of Cabot in the fourth quarter valued at approximately $79,000. Institutional investors and hedge funds own 86.61% of the company’s stock.
A number of equities research analysts have recently weighed in on the stock. ValuEngine upgraded shares of Cabot from a “strong sell” rating to a “sell” rating in a research report on Thursday, April 18th. Zacks Investment Research upgraded shares of Cabot from a “sell” rating to a “hold” rating in a research report on Tuesday, April 9th. Finally, TheStreet downgraded shares of Cabot from a “b-” rating to a “c+” rating in a research report on Friday, March 22nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $74.80.
Cabot (NYSE:CBT) last announced its quarterly earnings data on Monday, February 4th. The specialty chemicals company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The firm had revenue of $821.00 million during the quarter, compared to the consensus estimate of $778.50 million. Cabot had a net margin of 2.33% and a return on equity of 19.05%. The business’s revenue was up 14.0% compared to the same quarter last year. During the same period last year, the business earned $0.93 earnings per share. As a group, analysts anticipate that Cabot Corp will post 4.39 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Cabot Corp (CBT) Position Cut by MetLife Investment Advisors LLC” was published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/24/metlife-investment-advisors-llc-has-1-57-million-holdings-in-cabot-corp-cbt.html.
Cabot Corporation operates as a specialty chemicals and performance materials company. The company offers rubber grade carbon blacks used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and compounds of carbon black and rubber.
Featured Story: What is Depreciation?
Receive News & Ratings for Cabot Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabot and related companies with MarketBeat.com's FREE daily email newsletter.